Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence

被引:65
|
作者
Dasgupta, Paramita [1 ]
Baade, Peter D. [1 ,2 ,3 ]
Aitken, Joanne F. [1 ,4 ,5 ]
Ralph, Nicholas [5 ,6 ,7 ]
Chambers, Suzanne Kathleen [1 ,2 ,8 ,9 ]
Dunn, Jeff [1 ,5 ,9 ]
机构
[1] Canc Council Queensland, Canc Res Ctr, Brisbane, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Southport, Qld, Australia
[3] Queensland Univ Technol, Sch Math Sci, Brisbane, Qld, Australia
[4] Queensland Univ Technol, Sch Publ Hlth & Social Work, Brisbane, Qld, Australia
[5] Univ Southem Queensland, Inst Resilient Reg, Toowoomba, Qld, Australia
[6] St Vincents Private Hosp, Toowoomba, Qld, Australia
[7] Univ Southern Queensland, Sch Nursing 8 Midwifery, Toowoomba, Qld, Australia
[8] Edith Cowan Univ, Hlth & Wellness Inst, Perth, WA, Australia
[9] Univ Technol, Fac Hlth, Sydney, NSW, Australia
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
基金
英国医学研究理事会;
关键词
prostate cancer; rural; area-disadvantage; health disparity; systematic review; geographical variations; continuum of care; LEVEL SOCIOECONOMIC-STATUS; URBAN-RURAL DIFFERENCES; NEW-SOUTH-WALES; UNITED-STATES; RADICAL PROSTATECTOMY; POPULATION-DENSITY; AREA-LEVEL; MULTILEVEL ANALYSIS; HEALTH DISPARITIES; RADIATION-THERAPY;
D O I
10.3389/fonc.2019.00238
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Previous reviews of geographical disparities in the prostate cancer continuum from diagnosis to mortality have identified a consistent pattern of poorer outcomes with increasing residential disadvantage and for rural residents. However, there are no contemporary, systematic reviews summarizing the latest available evidence. Our objective was to systematically review the published international evidence for geographical variations in prostate cancer indicators by residential rurality and disadvantage. Methods: Systematic searches of peer-reviewed articles in English published from 1/1/1998 to 30/06/2018 using PubMed, EMBASE, CINAHL, and Informit databases. Inclusion criteria were: population was adult prostate cancer patients; outcome measure was PSA testing, prostate cancer incidence, stage at diagnosis, access to and use of services, survival, and prostate cancer mortality with quantitative results by residential rurality and/or disadvantage. Studies were critically appraised using amodified Newcastle-Ottawa Scale. Results: Overall 169 studies met the inclusion criteria. Around 50% were assessed as high quality and 50% moderate. Men from disadvantaged areas had consistently lower prostate-specific antigen (PSA) testing and prostate cancer incidence, poorer survival, more advanced disease and a trend toward higher mortality. Although less consistent, predominant patterns by rurality were lower PSA testing, prostate cancer incidence and survival, but higher stage disease and mortality among rural men. Both geographical measures were associated with variations in access and use of prostate cancer-related services for low to high risk disease. Conclusions: This review found substantial evidence that prostate cancer indicators varied by residential location across diverse populations and geographies. While wide variations in study design limited comparisons across studies, our review indicated that internationally, men living in disadvantaged areas, and to a lesser extent more rural areas, face a greater prostate cancer burden. This review highlights the need for a better understanding of the complex social, environmental, and behavioral reasons for these variations, recognizing that, while important, geographical access is not the only issue. Implementing research strategies to help identify these processes and to better understand the central role of disadvantage to variations in health outcome are crucial to inform the development of evidence-based targeted interventions.
引用
收藏
页数:35
相关论文
共 50 条
  • [21] Limited evidence for the use of imaging to detect prostate cancer: A systematic review
    Blomqvist, L.
    Carlsson, S.
    Gjertsson, P.
    Heintz, E.
    Hultcrantz, M.
    Mejare, I.
    Andren, O.
    EUROPEAN JOURNAL OF RADIOLOGY, 2014, 83 (09) : 1601 - 1606
  • [22] Evidence for a causal role by human papillomaviruses in prostate cancer – a systematic review
    James S. Lawson
    Wendy K. Glenn
    Infectious Agents and Cancer, 15
  • [23] Available evidence on HIFU for focal treatment of prostate cancer: a systematic review
    Bakavicius, Arnas
    Marra, Giancarlo
    Macek, Petr
    Robertson, Cary
    Abreu, Andre L.
    George, Arvin K.
    Malavaud, Bernard
    Coloby, Patrick
    Rischmann, Pascal
    Moschini, Marco
    Rastinehad, Ardeshir R.
    Sidana, Abhinav
    Stabile, Armando
    Tourinho-Barbosa, Rafael
    de la Rosette, Jean
    Ahmed, Hashim
    Polascik, Thomas
    Cathelineau, Xavier
    Sanchez-Salas, Rafael
    INTERNATIONAL BRAZ J UROL, 2022, 48 (02): : 263 - 274
  • [24] International epidemiology of prostate cancer: Geographical distribution and secular trends
    Baade, Peter D.
    Youlden, Danny R.
    Krnjacki, Lauren J.
    MOLECULAR NUTRITION & FOOD RESEARCH, 2009, 53 (02) : 171 - 184
  • [25] A systematic review of physical activity in prostate cancer survivors:: outcomes, prevalence, and determinants
    Thorsen, Lene
    Courneya, Kerry S.
    Stevinson, Clare
    Fossa, Sophie D.
    SUPPORTIVE CARE IN CANCER, 2008, 16 (09) : 987 - 997
  • [26] A SYSTEMATIC REVIEW OF CYTOREDUCTIVE PROSTATECTOMY OUTCOMES AND COMPLICATIONS IN PATIENTS WITH OLIGOMETASTATIC PROSTATE CANCER
    Morozov, Andrey
    Chuvalov, Leonid
    Enikeev, Mikhail
    Taratkin, Mark
    Enikeev, Dmitry
    JOURNAL OF UROLOGY, 2021, 206 : E364 - E365
  • [27] A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants
    Lene Thorsen
    Kerry S. Courneya
    Clare Stevinson
    Sophie D. Fosså
    Supportive Care in Cancer, 2008, 16 : 987 - 997
  • [28] A systematic review regarding outcomes and toxicities of re-irradiation for prostate cancer
    Rosa, C.
    Munoz, F.
    Fiorica, F.
    Caravatta, L.
    Ferella, L.
    Boldrini, L.
    Fionda, B.
    Alitto, A. R.
    Nardangeli, A.
    Dionisi, F.
    Pontoriero, A.
    Arcangeli, S.
    Di Marzo, A.
    Donato, V.
    Massaccesi, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1132 - S1133
  • [29] INTERNATIONAL VARIATIONS IN QUALITY METRICS FOR LOCALIZED PROSTATE CANCER
    Adam, Weiner B.
    Anissa, Nguyen, V
    Robert, Reiter E.
    Mark, Litwin S.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S91 - S91
  • [30] Evidence for bisphosphonates in prostate cancer: Systematic review of clodronate, etidronate, pamidronate and zoledronate
    Hunfeld, N. G. M.
    Kropman, R. F.
    Pelger, R. C. M.
    Le Brun, P. P. H.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 724 - 724